ASX - By Stock
|
PTX |
Re:
Next Biotech article
|
|
AMS71
|
115 |
50K |
3 |
18/05/18 |
18/05/18 |
ASX - By Stock
|
115
|
50K
|
3
|
|
ASX - By Stock
|
PTX |
Next Biotech article
|
|
AMS71
|
115 |
50K |
13 |
17/05/18 |
17/05/18 |
ASX - By Stock
|
115
|
50K
|
13
|
|
ASX - By Stock
|
PTX |
Re:
ABC: Cancer treatment shows promise
|
|
AMS71
|
5 |
2.5K |
3 |
24/04/18 |
24/04/18 |
ASX - By Stock
|
5
|
2.5K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Appendix 3B
|
|
AMS71
|
19 |
7.9K |
1 |
06/04/18 |
06/04/18 |
ASX - By Stock
|
19
|
7.9K
|
1
|
|
ASX - By Stock
|
PTX |
Newsflash...PTX in the press
|
|
AMS71
|
0 |
565 |
9 |
29/03/18 |
29/03/18 |
ASX - By Stock
|
0
|
565
|
9
|
|
ASX - By Stock
|
PTX |
USA is watching PTX
|
|
AMS71
|
74 |
31K |
16 |
08/12/17 |
08/12/17 |
ASX - By Stock
|
74
|
31K
|
16
|
|
ASX - By Stock
|
PTX |
Re:
Ann: AGM Presentation
|
|
AMS71
|
12 |
4.3K |
4 |
22/11/17 |
22/11/17 |
ASX - By Stock
|
12
|
4.3K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
|
|
AMS71
|
10 |
2.6K |
2 |
07/11/17 |
07/11/17 |
ASX - By Stock
|
10
|
2.6K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
|
|
AMS71
|
10 |
2.6K |
4 |
06/11/17 |
06/11/17 |
ASX - By Stock
|
10
|
2.6K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
|
|
AMS71
|
10 |
2.6K |
4 |
06/11/17 |
06/11/17 |
ASX - By Stock
|
10
|
2.6K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Prescient to resume AML trial
|
|
AMS71
|
21 |
5.7K |
2 |
04/09/17 |
04/09/17 |
ASX - By Stock
|
21
|
5.7K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Clinical Trial Update
|
|
AMS71
|
19 |
9.3K |
3 |
29/06/17 |
29/06/17 |
ASX - By Stock
|
19
|
9.3K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Gold Coast Investor Conference Presentation
|
|
AMS71
|
6 |
3.0K |
2 |
22/06/17 |
22/06/17 |
ASX - By Stock
|
6
|
3.0K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Successful Completion of Phase 1b Breast Cancer Trial
|
|
AMS71
|
24 |
8.0K |
1 |
07/04/17 |
07/04/17 |
ASX - By Stock
|
24
|
8.0K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Successful Completion of Phase 1b Breast Cancer Trial
|
|
AMS71
|
24 |
8.0K |
4 |
07/04/17 |
07/04/17 |
ASX - By Stock
|
24
|
8.0K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Three Additional US Patents Granted
|
|
AMS71
|
3 |
1.9K |
4 |
16/03/17 |
16/03/17 |
ASX - By Stock
|
3
|
1.9K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: First Cohort Successfully Completed in Phase 1b/2 AML Trial
|
|
AMS71
|
6 |
2.2K |
5 |
08/03/17 |
08/03/17 |
ASX - By Stock
|
6
|
2.2K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX to present at 29th Annual ROTH Conference
|
|
AMS71
|
3 |
1.5K |
3 |
04/03/17 |
04/03/17 |
ASX - By Stock
|
3
|
1.5K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
VHL - Transgene TG4011 & TG4010
|
|
AMS71
|
4 |
1.6K |
2 |
11/01/17 |
11/01/17 |
ASX - By Stock
|
4
|
1.6K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
VHL - Transgene TG4011 & TG4010
|
|
AMS71
|
4 |
1.6K |
2 |
11/01/17 |
11/01/17 |
ASX - By Stock
|
4
|
1.6K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
2017: A catalyst for PTX?
|
|
AMS71
|
6 |
2.8K |
5 |
07/01/17 |
07/01/17 |
ASX - By Stock
|
6
|
2.8K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: First Patient Dosed on Phase 1b/2 AML Trial
|
|
AMS71
|
13 |
4.7K |
4 |
14/12/16 |
14/12/16 |
ASX - By Stock
|
13
|
4.7K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: First Patient Dosed on Phase 1b/2 AML Trial
|
|
AMS71
|
13 |
4.7K |
6 |
14/12/16 |
14/12/16 |
ASX - By Stock
|
13
|
4.7K
|
6
|
|
ASX - By Stock
|
PTX |
Re:
PTX makes my Disallowed list
|
|
AMS71
|
62 |
17K |
2 |
30/08/16 |
30/08/16 |
ASX - By Stock
|
62
|
17K
|
2
|
|
ASX - By Stock
|
PTX |
Significance of Professor Jeffrey Lancet MD for PTX AML trial
|
|
AMS71
|
1 |
567 |
3 |
25/08/16 |
25/08/16 |
ASX - By Stock
|
1
|
567
|
3
|
|
ASX - By Stock
|
PTX |
Re:
PTX makes my Disallowed list
|
|
AMS71
|
62 |
17K |
1 |
23/08/16 |
23/08/16 |
ASX - By Stock
|
62
|
17K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
Ann: USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX
|
|
AMS71
|
6 |
1.9K |
2 |
04/08/16 |
04/08/16 |
ASX - By Stock
|
6
|
1.9K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Amended Share Trading Policy-PTX.AX
|
|
AMS71
|
4 |
1.4K |
3 |
27/07/16 |
27/07/16 |
ASX - By Stock
|
4
|
1.4K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Amended Share Trading Policy-PTX.AX
|
|
AMS71
|
4 |
1.4K |
1 |
20/07/16 |
20/07/16 |
ASX - By Stock
|
4
|
1.4K
|
1
|
|
ASX - By Stock
|
PTX |
BlueChip interview with PTX ED Paul Hopper
|
|
AMS71
|
0 |
444 |
4 |
12/07/16 |
12/07/16 |
ASX - By Stock
|
0
|
444
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Biotech shareholder expectations article
|
|
AMS71
|
6 |
2.1K |
5 |
08/07/16 |
08/07/16 |
ASX - By Stock
|
6
|
2.1K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX
|
|
AMS71
|
2 |
908 |
2 |
15/06/16 |
15/06/16 |
ASX - By Stock
|
2
|
908
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Notice of General Meeting/Proxy Form-PTX.AX
|
|
AMS71
|
23 |
4.9K |
4 |
07/06/16 |
07/06/16 |
ASX - By Stock
|
23
|
4.9K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX Secures $7.0M Capital Raising-PTX.AX
|
|
AMS71
|
7 |
3.0K |
0 |
18/05/16 |
18/05/16 |
ASX - By Stock
|
7
|
3.0K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX Secures $7.0M Capital Raising-PTX.AX
|
|
AMS71
|
7 |
3.0K |
2 |
18/05/16 |
18/05/16 |
ASX - By Stock
|
7
|
3.0K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Trading Halt-PTX.AX
|
|
AMS71
|
8 |
2.8K |
4 |
16/05/16 |
16/05/16 |
ASX - By Stock
|
8
|
2.8K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: March 2016 Appendix 4C - Quarterly-PTX.AX
|
|
AMS71
|
2 |
1.2K |
4 |
21/04/16 |
21/04/16 |
ASX - By Stock
|
2
|
1.2K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Edison Investment Research Initiates Coverage
|
|
AMS71
|
3 |
1.5K |
4 |
03/03/16 |
03/03/16 |
ASX - By Stock
|
3
|
1.5K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX-200 Breast Cancer Trial Progresses
|
|
AMS71
|
5 |
2.0K |
4 |
17/02/16 |
17/02/16 |
ASX - By Stock
|
5
|
2.0K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Steven Yatomi-Clarke Appointed CEO
|
|
AMS71
|
4 |
2.1K |
1 |
15/02/16 |
15/02/16 |
ASX - By Stock
|
4
|
2.1K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX Presents at NobleCon12
|
|
AMS71
|
6 |
1.9K |
3 |
21/01/16 |
21/01/16 |
ASX - By Stock
|
6
|
1.9K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Appendix 3B - Release of securities from escrow
|
|
AMS71
|
6 |
1.9K |
5 |
24/12/15 |
24/12/15 |
ASX - By Stock
|
6
|
1.9K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Release of Securities from Escrow
|
|
AMS71
|
7 |
2.1K |
5 |
10/12/15 |
10/12/15 |
ASX - By Stock
|
7
|
2.1K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Change of Director's Interest Notice
|
|
AMS71
|
2 |
804 |
3 |
08/12/15 |
08/12/15 |
ASX - By Stock
|
2
|
804
|
3
|
|
ASX - By Stock
|
PTX |
Re:
Ann: H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
|
|
AMS71
|
15 |
3.8K |
0 |
07/12/15 |
07/12/15 |
ASX - By Stock
|
15
|
3.8K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
Ann: H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
|
|
AMS71
|
15 |
3.8K |
3 |
02/12/15 |
02/12/15 |
ASX - By Stock
|
15
|
3.8K
|
3
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Share Purchase Plan Results
|
|
AMS71
|
5 |
1.3K |
0 |
28/11/15 |
28/11/15 |
ASX - By Stock
|
5
|
1.3K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
Ann: MD Anderson Leukaemia Expert Joins PTX SAB
|
|
AMS71
|
2 |
812 |
4 |
26/11/15 |
26/11/15 |
ASX - By Stock
|
2
|
812
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Share Purchase Plan Offer Document
|
|
AMS71
|
15 |
3.7K |
0 |
17/11/15 |
17/11/15 |
ASX - By Stock
|
15
|
3.7K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Share Purchase Plan Offer Document
|
|
AMS71
|
15 |
3.7K |
3 |
17/11/15 |
17/11/15 |
ASX - By Stock
|
15
|
3.7K
|
3
|
|